13 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 7 with minor changes only.
Primary completion pushed from Nov 2026 to Jul 2027
Also in this update: Study completion pushed from Nov 2028 to Jul 2029
Boston Scientific CorporationNot applicable NCT07015424 Registry history of NCT07015424 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2029 to Dec 2039
Boston Scientific CorporationNot specified NCT04032470 Registry history of NCT04032470 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: not specified → not applicable; Sponsor changed: [Redacted] to Boston Scientific Corporation
Boston Scientific CorporationNot applicable NCT07287436 Registry history of NCT07287436 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Boston Scientific CorporationNot specified NCT07455747 Registry history of NCT07455747 on ClinicalTrials.gov (opens the registry)
Start date pushed from Oct 31, 2026 to Nov 30, 2026
Boston Scientific CorporationNot specified NCT07458243 Registry history of NCT07458243 on ClinicalTrials.gov (opens the registry)
Primary completion moved earlier from Jul 2028 to Jan 2027
Also in this update: Study completion moved earlier from Dec 2030 to Jan 2027
Boston Scientific CorporationNot applicable NCT07187115 Registry history of NCT07187115 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 189 participants (planned 1000)
Boston Scientific CorporationNot specified NCT07262255 Registry history of NCT07262255 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Boston Scientific CorporationNot specified NCT06762717 Registry history of NCT06762717 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Boston Scientific CorporationNot applicable NCT06735534 Registry history of NCT06735534 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 31, 2026 to Jan 31, 2027
Also in this update: Study completion pushed from Apr 30, 2027 to Jun 30, 2027
Boston Scientific CorporationPhase 1 NCT05303467 Registry history of NCT05303467 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 83 → 86 locations
Boston Scientific CorporationNot specified NCT04674969 Registry history of NCT04674969 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 12 locations
Boston Scientific CorporationNot applicable NCT07575269 Registry history of NCT07575269 on ClinicalTrials.gov (opens the registry)
Start date pushed from Oct 2026 to Nov 2026
Boston Scientific CorporationNot applicable NCT07035431 Registry history of NCT07035431 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-09 | NCT07867886 An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM)… | Not Yet Recruiting |
| Phase 1 | 1 | |
| Phase 2 | 1 | |
| Phase 3 | 2 | |
| Phase 4 | 1 |
Heart Disease (29) · Atrial Fibrillation (19) · Stroke (4) · Liver Cancer (3) · Parkinson's Disease (3) · Glioblastoma (2) · Glioma (2) · Heart Failure (2) · Obesity (2) · Prostate Cancer (2)